New Delhi, Nov 18 (IANS) If you are taking Omega-3 pills or relish two-three servings of Omega-3 rich fish a week, you can continue with those, without worrying about its potential prostate cancer risk that some previous research with preliminary findings have reported in the past.
The researchers at the Intermountain Healthcare Heart Institute in Salt Lake City, Utah who continue to research the potential benefits and risks of this popular fish oil supplement — especially when it comes to prostate cancer risk and heart health — have found no link between the two.
The Intermountain research team presented two new studies about omega-3s at the ‘2019 American Heart Association Scientific Sessions’ in Philadelphia on Sunday.
In one study, the research team identified 87 patients who were part of the Intermountain ‘INSPIRE Registry’ and had developed prostate cancer.
These patients were also tested for plasma levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are two common omega-3 fatty acids.
When compared to a matched control group of 149 men, the researchers found that higher omega-3 levels were not linked with elevated prostate cancer risk.
Viet T Le from Intermountain Healthcare Heart Institute said they undertook this study in light of findings from a 2013 paper from the Journal of the National Cancer Institute that suggested a possible link between higher omega-3 plasma levels and the development of prostate cancer, one that has been debated since publication.
‘If I’m recommending omega-3 for my patients to save their hearts, I want to make sure I’m not putting them at risk for prostate cancer,’ said Le.
‘Our study found no evidence of a link between the two.’
In the second study, the researchers looked at 894 patients undergoing coronary angiography (a test that shows how blood flows through the arteries in the heart).
These patients had no prior history of heart attack or coronary artery disease, however upon their first angiogram, about 40 per cent of those patients had severe disease and about 10 per cent had three-vessel disease, Le said.
Researchers also measured patients’ plasma levels of omega-3 metabolites, including DHA and EPA. Those patients were then followed to see who had subsequent heart attack, stroke, heart failure, or who died.
They found that patients who had higher rates of omega-3 metabolites had a lower risk of those follow up adverse effects regardless of whether they had severe disease or not on their initial angiogram.
‘This study is important because we looked at how omega-3 helps patients who have already developed disease, and its effects on survival – both in getting to the first angiography to be diagnosed (vs. having a heart attack or worse before even knowing they have heart disease) and thereafter,’ Le elaborated.
While a seeming association between higher plasma omega-3 levels and the findings of severe heart disease upon initial angiogram might raise alarms that omega-3 isn’t beneficial, ‘they did live to see a doctor and get diagnosed,’ Le added.
‘And we saw a link between higher levels of omega-3 and their survival rate thereafter,’ they wrote.